Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs cyclophosphamide/azathioprine for generalised ANCA-associated vasculitis
2005-003610-15Phase 4Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Sustained remission. Started Sep 2005; status: completed.
02
Drugs
rituximab
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2005-003610-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003610-15.